Positive Phase II study shows similar clinical outcomes of immunotherapy and antibiotic treatment for recurrent acute cystitis, potentially reducing the need for antibiotics

Hamlet BioPharma – the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections – has

READ MORE

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer

Osaka, Japan & Cambridge, Mass., United States:   − Approval Based on Results from Positive, Global, Phase 3 FRESCO-2 Trial −

READ MORE